These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 25562126

  • 1. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits.
    Kane FE, Green KE.
    J Ocul Pharmacol Ther; 2015 Feb; 31(1):11-6. PubMed ID: 25562126
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.
    Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA.
    J Ocul Pharmacol Ther; 2004 Jun; 20(3):269-75. PubMed ID: 15279731
    [Abstract] [Full Text] [Related]

  • 4. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
    Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F, Famous Study Group.
    Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P, Khalatbari D, Yang P, Stinnett S, Tano R, Ashton P, Guo H, Nazzaro M, Jaffe GJ.
    Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
    Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K, FAME Study Group.
    Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes.
    Bhagat R, Zhang J, Farooq S, Li XY.
    J Ocul Pharmacol Ther; 2014 Dec; 30(10):854-8. PubMed ID: 25411827
    [Abstract] [Full Text] [Related]

  • 13. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
    Okabe K, Kimura H, Okabe J, Ogura Y.
    Retina; 2007 Dec; 27(6):770-7. PubMed ID: 17621189
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ocular pharmacokinetics profile of different indomethacin topical formulations.
    Bucolo C, Melilli B, Piazza C, Zurria M, Drago F.
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
    [Abstract] [Full Text] [Related]

  • 17. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR, Cason MM, Womble SW, Li G, Chastain JE.
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies.
    Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD.
    Drug Des Devel Ther; 2023 May; 17():961-975. PubMed ID: 37020801
    [Abstract] [Full Text] [Related]

  • 19. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
    Behar-Cohen FF, El Aouni A, Gautier S, David G, Davis J, Chapon P, Parel JM.
    Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.